Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

BACKGROUND: Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of Alzheimer's disease (AD). Data supporting the safety and efficacy of second-generation cholinesterase inhibitors, such as rivastigmine, are available for treatment up to 1 year, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Farlow, Martin R, Lilly, Mary L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548267/
https://www.ncbi.nlm.nih.gov/pubmed/15659242
http://dx.doi.org/10.1186/1471-2318-5-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548267/
https://www.ncbi.nlm.nih.gov/pubmed/15659242
http://dx.doi.org/10.1186/1471-2318-5-3

Ejemplares similares